Background Oral pre-exposure prophylaxis has been introduced in more than 70 countries,
including many in sub-Saharan Africa, but women experience considerable barriers to daily …

Abstract Introduction Pre‐exposure prophylaxis (PrEP) is an important HIV prevention
option. Two randomized trials have provided efficacy evidence for long‐acting injectable …

Worldwide, women face compounding reproductive health risks, including human
immunodeficiency virus (HIV), sexually-transmitted infections (STIs), and unintended …

In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may
be offered as an additional HIV prevention option for people at substantial risk of HIV …

Introduction: Existing biomedical HIV prevention options, though highly effective, present
substantial adherence challenges. End-user input on early-stage design of new HIV …

Background: Integrating end-user perspectives into the design of new biomedical HIV
prevention products is recognized as vital to informing the product development pipeline …

Introduction Preventing HIV and unintended pregnancies are key global health priorities. To
inform product rollout and to understand attributes of future multipurpose prevention …

Background Long-acting injectable cabotegravir, a drug taken every 2 months, has been
shown to be more effective at preventing HIV infection than daily oral tenofovir disoproxil …

Background We aimed to systematically review the health preference literature using
discrete choice experiments (DCEs), an attribute-based stated preference method, to …

Women need multipurpose prevention technologies (MPTs) to simultaneously prevent
sexually transmitted infections (STIs), including HIV, with or without contraception. User …